# Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

> **NCT05293509** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Stem Cell Transplantation

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Dexamethasone
- **DRUG:** Cyclophosphamide
- **DRUG:** Bortezomib
- **DRUG:** Rituximab
- **DRUG:** Busulfan
- **DRUG:** Cyclophosphamide (Cy)
- **DRUG:** Tacrolimus (or cyclosporine)
- **DRUG:** Mycophenolate mofetil (MMF)
- **DRUG:** Rabbit ATG

## Key facts

- **NCT ID:** NCT05293509
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-02
- **Primary completion:** 2023-09-18
- **Final completion:** 2023-09-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 accrual
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05293509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05293509, "Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05293509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*